HLS Therapeutics (TSE:HLS) Given New C$5.00 Price Target at Raymond James

HLS Therapeutics (TSE:HLS) had its target price upped by Raymond James from C$4.00 to C$5.00 in a report released on Friday,BayStreet.CA reports.

Separately, Stifel Nicolaus dropped their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

HLS Therapeutics Price Performance

HLS opened at C$3.42 on Friday. The firm has a market cap of C$108.72 million, a price-to-earnings ratio of -3.39 and a beta of 1.07. HLS Therapeutics has a fifty-two week low of C$3.00 and a fifty-two week high of C$5.48. The company’s 50-day moving average price is C$3.54 and its 200 day moving average price is C$3.51. The company has a quick ratio of 1.01, a current ratio of 2.02 and a debt-to-equity ratio of 100.44.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.